

October 14, 2024  
Web Announcement 3461

## Respiratory Syncytial Virus (RSV) Prophylaxis with Synagis® (palivizumab)

Nevada RSV coverage season will open from November 1, 2024, through March 31, 2025. Reimbursement from Nevada Medicaid is only authorized during this time. Providers may submit prior authorization (PA) requests for Synagis® beginning October 21, 2024. Providers may submit claims for approved Synagis® PAs beginning November 1, 2024.

Any PA requests for Synagis® reimbursement outside of the RSV season (November 1, 2024, through March 31, 2025) will require clinical justification from the provider for consideration, including information on the RSV rates within the patient's specific community.

The clinical criteria used by Nevada Medicaid for the 2024-2025 RSV season is consistent with guidance published by the American Academy of Pediatrics (AAP). RSV activity will be closely monitored during the five-month time frame to determine if the season length should be adjusted. Providers are encouraged to review the updated AAP guidelines regarding RSV treatment for the upcoming season<sup>1</sup>.

Per FDA Label, children who have received Beyfortus® are not eligible to receive Synagis® for the same RSV season<sup>2</sup>.

The Synagis® prior authorization request form ([FA-65](#)) has been posted on the Prime Therapeutics web portal. please refer to the [pharmacy manual](#) for instructions on the Synagis® claim submissions.

For any questions, call the Prime Therapeutics call center for Nevada Medicaid at (800) 695-5526.

### Guidelines/References

1 <https://publications.aap.org/>

2 <https://products.sanofi.us/beyfortus/beyfortus.pdf>